Go Pro

MorphoSys (MPSYF) 10K Form and Latest SEC Filings 2026

MorphoSys logo
$73.27 0.00 (0.00%)
As of 09/11/2026

Latest MorphoSys SEC Filings & Recent Activity

MorphoSys (OTCMKTS:MPSYF) has submitted 553+ documents to the U.S. Securities and Exchange Commission (SEC) since 2018. For investors, these filings are the primary source of verified financial data — covering everything from annual revenue and debt levels in the 10-K, to material business events in 8-K current reports, to insider buying and selling activity in Form 4 disclosures. The most recent filing was a Form 15-12G submitted on October 17, 2024.

DateFilerForm TypeView
10/17/2024 3:54 PM
MorphoSys (1340243) Filer
Form 15-12G
10/04/2024 3:21 PM
MorphoSys (1340243) Filer
Form S-8 POS
10/04/2024 3:24 PM
MorphoSys (1340243) Filer
Form S-8 POS
10/04/2024 3:27 PM
MorphoSys (1340243) Filer
Form S-8 POS
10/04/2024 3:30 PM
MorphoSys (1340243) Filer
Form S-8 POS
10/04/2024 3:33 PM
MorphoSys (1340243) Filer
Form S-8 POS
10/04/2024 3:36 PM
MorphoSys (1340243) Filer
Form S-8 POS
10/04/2024 3:18 PM
MorphoSys (1340243) Filer
Form S-8 POS
10/04/2024 3:16 PM
MorphoSys (1340243) Filer
Form POSASR
08/27/2024 9:14 AM
MorphoSys (1340243) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
08/15/2024 3:30 PM
MorphoSys (1340243) Subject
NOVARTIS AG (1114448) Filed by
Form SC 13D/A
08/13/2024 3:31 PM
MorphoSys (1340243) Subject
NOVARTIS AG (1114448) Filed by
Form SC TO-T/A
08/07/2024 3:51 PM
MorphoSys (1340243) Subject
Form SC 14D9/A
08/07/2024 3:30 PM
MorphoSys (1340243) Subject
NOVARTIS AG (1114448) Filed by
Form SC TO-T/A
08/05/2024 7:14 AM
MorphoSys (1340243) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
08/02/2024 3:30 PM
MorphoSys (1340243) Subject
NOVARTIS AG (1114448) Filed by
Form SC TO-T/A
08/01/2024 3:30 PM
MorphoSys (1340243) Subject
NOVARTIS AG (1114448) Filed by
Form SC TO-T/A
07/31/2024 3:30 PM
MorphoSys (1340243) Subject
NOVARTIS AG (1114448) Filed by
Form SC TO-T/A
07/30/2024 3:30 PM
MorphoSys (1340243) Subject
NOVARTIS AG (1114448) Filed by
Form SC TO-T/A
07/29/2024 3:30 PM
MorphoSys (1340243) Subject
NOVARTIS AG (1114448) Filed by
Form SC TO-T/A
07/25/2024 3:30 PM
MorphoSys (1340243) Subject
NOVARTIS AG (1114448) Filed by
Form SC TO-T/A
07/25/2024 3:05 PM
MorphoSys (1340243) Filer
Form 25
Notification of the removal from listing and registration of matured, redeemed or retired securities  
07/18/2024 3:30 PM
MorphoSys (1340243) Subject
NOVARTIS AG (1114448) Filed by
Form SC TO-T/A
07/18/2024 10:25 AM
MorphoSys (1340243) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
07/12/2024 3:20 PM
MorphoSys (1340243) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
07/11/2024 3:30 PM
MorphoSys (1340243) Subject
NOVARTIS AG (1114448) Filed by
Form SC TO-T/A
07/05/2024 5:48 AM
MorphoSys (1340243) Subject
Form SC 14D9
07/05/2024 5:02 AM
MorphoSys (1340243) Subject
NOVARTIS AG (1114448) Filed by
Form SC TO-T
07/02/2024 9:18 AM
MorphoSys (1340243) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
06/21/2024 3:30 PM
MorphoSys (1340243) Subject
NOVARTIS AG (1114448) Filed by
Form SC 13D/A
06/21/2024 9:07 AM
MorphoSys (1340243) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
06/20/2024 3:41 PM
MorphoSys (1340243) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
06/20/2024 3:33 PM
MorphoSys (1340243) Subject
Form SC14D9C
06/20/2024 2:38 PM
MorphoSys (1340243) Subject
NOVARTIS AG (1114448) Filed by
Form SC TO-C
06/17/2024 3:30 PM
MorphoSys (1340243) Subject
NOVARTIS AG (1114448) Filed by
Form SC 13D/A
06/10/2024 3:30 PM
MorphoSys (1340243) Subject
NOVARTIS AG (1114448) Filed by
Form SC 13D/A
06/10/2024 11:06 AM
GOLDMAN SACHS GROUP INC (886982) Filed by
MorphoSys (1340243) Subject
Form SC 13G/A
06/10/2024 10:01 AM
MorphoSys (1340243) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
06/06/2024 3:36 PM
MorphoSys (1340243) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
06/05/2024 9:22 AM
MorphoSys (1340243) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
06/04/2024 3:30 PM
MorphoSys (1340243) Subject
NOVARTIS AG (1114448) Filed by
Form SC TO-T/A
The only 5 stocks that matter (Ad)

SpaceX's IPO reportedly minted 4,400 new millionaires, and OpenAI is said to be eyeing a 1 trillion dollar IPO as soon as this fall. TradeSmith CEO Keith Kaplan says chasing the next hot IPO isn't necessary. His AI-driven system, built on a platform pioneered by Google, ranks every stock in the S&P 500 and narrows the list to just five names to hold each month. Backtests show the Top Five Stocks outperformed the S&P 500 by 4x in August alone.tc pixel

See the five stocks the AI system is tracking now
06/04/2024 9:17 AM
MorphoSys (1340243) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
05/31/2024 9:17 AM
MorphoSys (1340243) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
05/29/2024 9:17 AM
MorphoSys (1340243) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
05/28/2024 9:16 AM
MorphoSys (1340243) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
05/24/2024 9:13 AM
MorphoSys (1340243) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
05/23/2024 1:19 PM
MorphoSys (1340243) Subject
Form SC 14D9/A
05/23/2024 9:11 AM
MorphoSys (1340243) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
05/23/2024 8:04 AM
MorphoSys (1340243) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
05/21/2024 9:07 AM
MorphoSys (1340243) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
05/17/2024 9:15 AM
MorphoSys (1340243) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
05/16/2024 3:43 PM
MorphoSys (1340243) Subject
Form SC 14D9/A
05/16/2024 3:31 PM
MorphoSys (1340243) Subject
NOVARTIS AG (1114448) Filed by
Form SC TO-T/A
05/16/2024 9:11 AM
MorphoSys (1340243) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
05/15/2024 9:09 AM
MorphoSys (1340243) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
05/14/2024 9:27 AM
MorphoSys (1340243) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
05/13/2024 9:19 AM
MorphoSys (1340243) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
05/10/2024 9:31 AM
MorphoSys (1340243) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
05/08/2024 9:08 AM
MorphoSys (1340243) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
05/07/2024 3:45 PM
MorphoSys (1340243) Subject
NOVARTIS AG (1114448) Filed by
Form SC TO-T/A
05/07/2024 9:24 AM
MorphoSys (1340243) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
05/06/2024 3:30 PM
MorphoSys (1340243) Subject
NOVARTIS AG (1114448) Filed by
Form SC TO-T/A
05/06/2024 9:07 AM
MorphoSys (1340243) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
05/03/2024 9:29 AM
MorphoSys (1340243) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
05/02/2024 3:31 PM
MorphoSys (1340243) Subject
NOVARTIS AG (1114448) Filed by
Form SC TO-T/A
05/02/2024 9:43 AM
MorphoSys (1340243) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
04/30/2024 9:07 AM
MorphoSys (1340243) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
04/30/2024 7:57 AM
MorphoSys (1340243) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
04/29/2024 3:15 PM
MorphoSys (1340243) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
04/29/2024 9:17 AM
MorphoSys (1340243) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
04/26/2024 9:11 AM
MorphoSys (1340243) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
04/25/2024 3:30 PM
MorphoSys (1340243) Subject
NOVARTIS AG (1114448) Filed by
Form SC TO-T/A
04/25/2024 9:38 AM
MorphoSys (1340243) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
04/24/2024 10:03 AM
MorphoSys (1340243) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
04/23/2024 9:14 AM
MorphoSys (1340243) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
04/22/2024 9:32 AM
MorphoSys (1340243) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
04/19/2024 9:17 AM
MorphoSys (1340243) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
04/18/2024 3:31 PM
MorphoSys (1340243) Subject
NOVARTIS AG (1114448) Filed by
Form SC TO-T/A
04/18/2024 1:33 PM
MorphoSys (1340243) Subject
NOVARTIS AG (1114448) Filed by
Form SC 13D
04/18/2024 9:13 AM
MorphoSys (1340243) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
04/17/2024 3:49 PM
MorphoSys (1340243) Subject
Form SC 14D9/A
04/17/2024 3:30 PM
MorphoSys (1340243) Subject
NOVARTIS AG (1114448) Filed by
Form SC TO-T/A
04/16/2024 4:07 PM
MorphoSys (1340243) Subject
NOVARTIS AG (1114448) Filed by
Form SC TO-T/A
04/16/2024 9:12 AM
MorphoSys (1340243) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
04/15/2024 2:44 PM
MorphoSys (1340243) Subject
NOVARTIS AG (1114448) Filed by
Form SC TO-T/A
04/12/2024 9:54 AM
MorphoSys (1340243) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
04/11/2024 10:57 AM
MorphoSys (1340243) Subject
Form SC 14D9
04/11/2024 5:01 AM
MorphoSys (1340243) Subject
NOVARTIS AG (1114448) Filed by
Form SC TO-T
04/09/2024 9:07 AM
MorphoSys (1340243) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
04/08/2024 9:19 AM
MorphoSys (1340243) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
04/04/2024 9:15 AM
MorphoSys (1340243) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
Print this before your next trade (Ad)

Bill Poulos is offering his Smart Trade Options Checklist at no cost today - normally priced at $29.97. It's a single-page, seven-point filter designed to help traders identify weak setups before placing any options trade. Print it, keep it at your desk, and run it before every trade. The download link expires soon.tc pixel

Download your free copy of the Smart Trade Options Checklist now
04/02/2024 9:08 AM
MorphoSys (1340243) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
03/27/2024 12:16 PM
MorphoSys (1340243) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
03/26/2024 10:15 AM
MorphoSys (1340243) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
03/25/2024 10:37 AM
MorphoSys (1340243) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
03/22/2024 10:17 AM
MorphoSys (1340243) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
03/22/2024 5:47 AM
MorphoSys (1340243) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
03/21/2024 10:27 AM
MorphoSys (1340243) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
03/20/2024 3:12 PM
MorphoSys (1340243) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
03/20/2024 10:13 AM
MorphoSys (1340243) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
(Data available from 1/1/2016 forward)

MorphoSys SEC Filings - Frequently Asked Questions

MorphoSys (MPSYF) has submitted 553+ filings to the SEC since 2018. You can browse the complete history or filter by form type using the tools above.

The most recent filing was a Form 15-12G submitted on October 17, 2024. View the full filing using the link above.

SEC Filing Types: 10-K, 10-Q, 8-K and More

SEC filings are legally required disclosures that public companies submit to the U.S. Securities and Exchange Commission. Unlike press releases or earnings call transcripts, these documents are filed under legal obligation — meaning the financial data they contain is audited, standardized, and subject to penalties if materially false. For investors, that makes SEC filings the most reliable primary source available for evaluating a company's true financial position.

Yes. All SEC filings are publicly available through the SEC's EDGAR database and on financial research platforms like MarketBeat. Companies are required by law to make these disclosures accessible to all investors — meaning retail investors have access to the same source documents as institutional analysts.

A 10-K is an annual report containing audited financial statements and a full review of the company's business — it is the most comprehensive filing a company makes each year. A 10-Q is a shorter, unaudited quarterly update filed three times per year between annual reports. Investors typically use the 10-K for deep fundamental analysis and the 10-Q to track whether the company is on pace with its guidance mid-year.

The most important filing for fundamental investors. Filed once per year, the 10-K contains audited financial statements, revenue and earnings trends, debt obligations, risk factors, and management's own assessment of the business. Reading the risk factors section and comparing year-over-year financials can reveal issues that don't show up in analyst summaries.

An unaudited financial update filed three times per year (the 10-K covers Q4). Investors use 10-Qs to track whether guidance is on pace, monitor changes in cash flow or inventory, and catch any mid-year shifts in business conditions before they become headline news.

Filed within four business days of a material event — earnings releases, merger announcements, executive departures, or major asset sales. Because 8-Ks are filed before media coverage catches up, they are often the fastest way to get unfiltered information directly from the company on market-moving events.

Filed within two business days whenever an executive or director buys or sells company stock. Insider purchases — especially large or clustered buys — are often interpreted as a signal of management confidence. Insider selling is more ambiguous but worth monitoring for patterns, particularly around lock-up expirations or ahead of major announcements.


Related Companies and Tools


SEC filings for OTCMKTS:MPSYF are sourced directly from the U.S. Securities and Exchange Commission (SEC), with the most recent filing dated 10/17/2024. New filings are added as they're published.
From Our Partners